Tissue Regenix, Ltd.
Spun out of the University of Leeds in 2006, Tissue Regenix commercialise upon research undertaken by our higher education and research partners around the world.
Tissue Regenix listed on the Alternative Investment Market (AIM) on the London Stock Exchange in 2010, before opening the first subsidiary office Tissue Regenix Woundcare, Inc. in San Antonio, Texas in 2012.
In early 2016, Tissue Regenix entered its first joint venture establishing GBM-V , a Tissue Bank in Rostock, Germany, granting them the first licence for the production of dCELL® heart valves, and strengthening its presence within Europe.
Our patented dCELL® Technology products provide a natural alternative to harvesting and transplanting the patient’s own ligaments or tendons, eliminating any donor site complications (a second surgical site), supporting a replicable surgery, saving operating room time and simplifying rehabilitation.